Latest news with #ABCL
India.com
14 hours ago
- Entertainment
- India.com
This 28 year old film of Amitabh Bachchan was his biggest flop, even Jaya Bachchan walked out at the interval, film is.., lead actress was...
This 28 year old film of Amitabh Bachchan was his biggest flop, even Jaya Bachchan walked out at the interval, film is.., lead actress was... The megastar of Indian cinema, Amitabh Bachchan, has dominated Bollywood for decades with his famous roles and historic blockbusters. From the 'angry young man' of the 70s to his powerful characters in modern films, Bachchan has won the admiration and affection of generations. Although the majority of his films have been successful, not every film in his career was a hit. The film that we are talking about is none other than Mrityudaata. Released 28 years ago, this film stands to be the biggest career failure in Amitabh Bachchan's remarkable career. Produced by his own company ABCL and directed by Mehul Kumar, hopes were high. The supporting cast featured some strong performers like Karishma Kapoor, Paresh Rawal, Pran, and Dimple Kapadia opposite Amitabh, but no amount of anticipation could prepare audiences for the disaster Mrityudaata would become. What's surprising is that his wife, Jaya Bachchan, understood the fate of this movie early on. During the preview screening, she left at the interval. That was enough for Amitabh to know something was wrong. When he asked her why she left, Jaya replied that she had found the film boring, and it had not engaged her from the start. Much self-honesty as those predictions were, they were sadly true. The audience's lack of engagement and Dimple and Amitabh's on-screen chemistry did not create any lasting impression. The film failed to recover its budget as a commercial endeavor at the box office. Amitabh later took responsibility for the flop, admitting the film did not live up to expectations and he was partly to blame for finding it not good enough. After scoring a hit after a hit in the 70s and 80s, he was facing a series of flops, which started to erode his persona. Mrityudata, rather than being a comeback film, was just one more film on the wrong side of the ledger. Failure, however, is a reminder that legends also have lows and is, as always, an opportunity for courage, recognition of it, and rising again.
Yahoo
09-06-2025
- Business
- Yahoo
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio's Substack. In this article, we will summarize the bulls' thesis on ABCL. AbCellera Biologics Inc. (ABCL)'s share was trading at $2.14 as of 2nd June. ABCL's trailing P/E was 19.92 according to Yahoo Finance. A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. Abcellera is approaching a potential inflection point as it advances two new molecules—ABCL575 and ABCL635—into clinical trials, signaling its progress from a platform with promise to one capable of solving real-world medical problems. ABCL575 targets the OX-40 pathway, a critical immune regulator, and is being trialed for atopic dermatitis, with broader implications for treating alopecia and other chronic conditions that often stem from underlying viral or bacterial infections. CEO Carl Hansen noted that the same mechanism might have therapeutic value across autoimmune disorders, cancers, and infectious diseases, making OX-40 a cornerstone of Abcellera's ambitions. Meanwhile, ABCL635 targets the NK3R receptor in the brain's infundibular nucleus, effectively regulating endocrine balance and alleviating menopausal hot flashes. Since NK3R is part of the expansive GPCR receptor family, success here could validate Abcellera's ability to target a vast range of physiological functions, from hormone control to mood and sensory regulation. Both candidates exemplify the same core strength of Abcellera's platform: designing molecules with highly specific shapes to achieve precise biological effects. This shape-function relationship underpins the company's long-term vision of building a foundational biotech platform capable of producing tailored therapeutics. Although Abcellera's current financials remain weak, reflecting high risk, clinical success would dramatically increase its operating leverage and establish its relevance across a wide therapeutic spectrum. The platform's success could mirror and complement businesses like Hims, where data on bodily processes meets Abcellera's molecular solutions. While early in its journey, Abcellera's emerging capabilities suggest transformative potential if early trials succeed. Previously, we have covered ABCL in January 2025 wherein we summarized a by Jack Prescott on Twitter. The author highlighted the company's differentiated antibody discovery platform, which used microfluidics and AI to support an asset-light, partnership-driven model with firms like Eli Lilly and Moderna. Despite setbacks post-COVID, AbCellera maintained strong financials with $700M in cash, minimal debt, and over 200 pipeline programs, while its new GMP facility and government support positioned it for future clinical and commercial growth. Unfortunately, his thesis did not play out and the stock is down 26% since our coverage. However, due to the company's recent advances in the clinical trial process of two new molecules, we are optimistic about Antonio's thesis. AbCellera Biologics Inc. (ABCL) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held ABCL at the end of the first quarter which was 20 in the previous quarter. While we acknowledge the potential of ABCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
India.com
25-05-2025
- Entertainment
- India.com
Amitabh Bachchan once went bankrupt and it affected Mukul Dev's career in Bollywood due to...
Bollywood actor Amitabh Bachchan is the epitome of versatility. The actor has been contributing to Indian cinema for decades. Despite turning 82 years old, he has not stopped working. Amitabh Bachchan was last seen in the superhit film Kalki 2898 AD and the Shahenshah actor hosts the very famous quiz show Kaun Banega Crorepati. As a result, Amitabh Bachchan stands in the sixth spot in the top 10 richest Bollywood actors. However, while today Amitabh has all the luxury to himself, things were not the same when he started his own production house, ABCL. The actor faced many challenges and even bankruptcy. However, a chain reaction of events played a crucial role in launching the career of the late actor, Mukul Dev. Interesting right! Scroll down to read more. Do you know that Amitabh Bachchan's production house had signed Mukul Dev for his debut?! Yes, that's correct! In an interview, the late actor opened up on the matter and revealed that Jaya Bachchan had approached him with the offer to act in one of the three films which were being made by Big B's production company. He revealed that an advance payment of Rs 75,000 was also given to him. In the interview, Mukul Dev said, 'When she met me she had said, 'I want to sign you. We are making three films and you are doing at least one film with us among the three films that we are producing. I don't know which of these films you will do but you will do a film with us.'' The name of the film was Naam Kya Hai and it would have marked Mukul's debut in Bollywood. However, that never happened as the production house ran into financial loss and all the films that were being produced during that tenure were shelved. In a conversation with Planet Bollywood, the actor stated that Amitabh Bachchan had to face massive loss due to which the 2-3 movies which were made were never released. Amitabh Bachchan's company ABCL was facing major losses in the late 90s. In an interview with Vir Sanghvi, he opened up on the same and revealed that the company was of Rs 60 crore and it faced a loss of Rs 70 crore. Additionally, a debt of Rs 22 crore was on Big B's head. By the time Mukul Dev's movie was about to release, Amitabh Bachchan had incurred a loss of Rs 90 crores. As a result, Amitabh had no choice but to cancel the release. Meanwhile, Mukul Dev said goodbye to the world on May 24, 2025. The actor was not keeping well for a long time and passed away at the age of 54. He is survived by his brother Rahul Dev.
Time of India
25-05-2025
- Entertainment
- Time of India
Jaya Bachchan gave Rs 75,000 to Mukul Dev as a signing amount to launch him; his debut film got shelved as Amitabh Bachchan's company was going through financial crisis
Actor Mukul Dev passed away at the age of 54 on Friday in New Delhi and his death came as a huge shock everyone. Mukul was launched by Mahesh Bhatt in 'Dastak' which had him opposite Sushmita Sen . But did you know that Mukul's debut film was to be production by Amitabh Bachchan 's company ABCL ? Mukul had said in an interview that he also had received a signing amount from Jaya Bachchan . The film was titled 'Naam Kya Hai' but it never saw the light of the day due as Big B went through huge financial crisis and so did his production house. He had shared in an interview with Planet Bollywood, "Yes, the film was complete but it could never get a release for itself. ABCL was going through a financial crisis and a couple of other films that were produced by the company during that time did not release.' He added, "'My first income was Rs 75,000 and they were given by Jaya Bachchan for the ABCL film. When she met me she had said, 'I want to sign you. We are making three films and you are doing at least one film with us among the three films that we are producing. I don't know which of these films you will do but you will do a film with us.'' Dev just couldn't believe that Jaya Bachchan had offered him a film. He said, 'I even told her on phone, 'Who is this? Why are you joking with me?' Later when I realised it is her, I went to meet her.' Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Secure Your Child's Future with Strong English Fluency Planet Spark Learn More Undo After Mukul's death, his brother Rahul Dev expressed on social media, "We are deeply saddened to inform you that our brother Mukul Dev passed away peacefully last night in New Delhi. He is survived by his daughter, Sia Dev, and will be dearly missed by his siblings Rashmi Kaushal, Rahul Dev, and his nephew Sidhant Dev.' Check out our list of the latest Hindi , English , Tamil , Telugu , Malayalam , and Kannada movies . Don't miss our picks for the best Hindi movies , best Tamil movies, and best Telugu films .
News18
25-05-2025
- Entertainment
- News18
Mukul Dev Was Shocked When Amitabh, Jaya Bachchan Signed Him For Debut: 'Why Are You Joking?'
Last Updated: Actor Mukul Dev, who passed away at 54, on Saturday, once revealed his ABCL debut film with Jaya Bachchan never released. The entertainment industry is mourning the loss of actor Mukul Dev, who passed away at the age of 54. Known for his work across television and films, Mukul made his acting debut in Mahesh Bhatt's 1996 film Dastak. However, few know that his actual first project was a film that never saw the light of day. Before Dastak, Mukul had shot for a movie titled Naam Kya Hai, which was produced by Amitabh Bachchan's company ABCL. Unfortunately, the film was shelved and never released in theatres. In a past interview with Planet Bollywood, Mukul had opened up about the lost opportunity. 'Yes, the film was complete but it could never get a release for itself. ABCL was going through a financial crisis and a couple of other films that were produced by the company during that time did not release." In another older conversation with Lehren TV, he fondly remembered the signing amount he received for Naam Kya Hai, calling it his first income as an actor. 'My first income was Rs 75,000 and they were given by Jaya Bachchan for the ABCL film. When she met me she had said, 'I want to sign you. We are making three films and you are doing at least one film with us among the three films that we are producing. I don't know which of these films you will do but you will do a film with us.'" Mukul was surprised and initially doubtful when he received the call from Jaya Bachchan herself. 'I even told her on phone, 'Who is this? Why are you joking with me?' Later when I realised it is her, I went to meet her." Mukul had been unwell for the past few days and was admitted to the ICU. Despite all efforts, he could not recover. He is survived by his brother, actor Rahul Dev. Following his passing, Rahul Dev shared the sad news on X (formerly Twitter). 'We are deeply saddened to inform you that our brother Mukul Dev passed away peacefully last night in New Delhi. He is survived by his daughter, Sia Dev, and will be dearly missed by his siblings Rashmi Kaushal, Rahul Dev, and his nephew Sidhant Dev." First Published:
